Auranofin, an organogold compound classified as an anti-rheumatic agent is under phase 2 clinical trials for re-purposing to treat recurrent epithelial ovarian cancer. We have reported earlier that Breast cancer 1, early onset (BRCA1) mutant ovarian cancer cells exhibit increased sensitivity to auranofin. BRCA1 is a DNA repair protein whose functional status is critical in the prognosis of ovarian cancer. Apart from DNA repair capability of cancer cells, membrane fluidity is also implicated in modulating resistance to chemotherapeutics. We report here that 
Introduction
The dynamic nature of plasma membrane inferred as membrane fluidity is a critical physiochemical property that modulates cellular functions. Over the years, a significant number of studies have been undertaken to understand how membrane fluidity influences drug sensitivity in cancer cells (1) . Analysis of membrane dynamics of chemo-resistant cancer cells reveals rigidification of cell membranes (2) . The observed membrane rigidity of resistant cancer cells has been found to be due to the presence of relatively high amounts of cholesterol and sphingomyelin (3, 4) . Breast cancer cells were reported to have reduced expression of sphingomyelinase that catalyses the hydrolysis of sphingomyelin (5) . Recovering sphingomyelinase expression fluidizes the membrane and enhances drug transport which eventually leads to reversal of resistance (6) . Interestingly, the threshold concentration of internalised doxorubicin is the same for both resistant and sensitive cells suggesting drug uptake could be a major factor deciding the sensitivity of cancer cells (2) . Modulation of membrane fluidity by pharmacological agents has been demonstrated to increase the drug uptake and thereby sensitivity of cancer cells to chemotherapeutic agents (7) . The membrane lipid analysis of cisplatin and doxorubicin resistant breast cancer cells showed a high content of cholesterol and sphingomyelins which results in membrane rigidity (4) . Conversely, resistant cancer cells possess fewer amounts of diacyl and triacyl glycerols that are known to constitute a more fluid membrane (4) . A similar analysis of membrane phospholipids demonstrated qualitative and quantitative differences between malignant, benign and normal breast tissues (3) . Significantly distinguishable was lysophosphatidylcholine where its presence was remarkably decreased in malignant and benign tissues compared to normal breast tissues (3) . However, a comparative study of membrane fluidity and drug sensitivity of cancer cells of the same histological origin has not yet been performed.
Auranofin, a thioredoxin reductase inhibitor has been widely used for the treatment of rheumatoid arthritis under the proprietary name Ridaura. Auranofin has also been demonstrated to possess anti-cancer properties in both in vitro and in vivo conditions (8, 9) . Moreover, auranofin is currently undergoing phase 2 clinical trials for re-purposing to treat recurrent epithelial ovarian cancer (https://clinicaltrials.gov/ct2/show/NCT01747798). We have recently reported that genetic depletion of BRCA1 sensitizes ovarian cancer cells to auranofin (10) .
Auranofin induces lethal DNA double strand breaks (DSBs) and apoptosis in BRCA1 deficient ovarian cancer cells (10) . Anti-oxidant mediated protection of BRCA1 deficient cells suggest that reactive oxygen species (ROS) plays a critical role in auranofin induced DNA damage and apoptosis (10) .
Membrane fluidity is often studied in association with intracellular drug uptake (2,7). However, early increase in membrane fluidity is critical in modulating cellular response to chemotherapeutic drugs such as cisplatin (11) . Interestingly, blocking the early increase in membrane fluidity by pharmacological means inhibit apoptosis despite the intracellular uptake and formation of cisplatin DNA adducts (11) . This suggests that changes in membrane fluidity induced by chemotherapeutic drugs may regulate cellular fate which is a critical and independent process from intracellular drug uptake and its targets. Furthermore, this also points that membrane fluidity is a critical physiochemical parameter that could potentially modulate multiple processes from drug entry to induced cellular outcome. However, a correlative study investigating the role of inherent membrane fluidity in regulating the genotoxic and cytotoxic effects of drugs has yet to be established. Adopting an integrated approach, in this study we therefore aimed to elucidate how plasma membrane fluidity could modulate cytotoxic and genotoxic responses of ovarian cancer cell lines (IGROV1 & OVCAR5) of adenocarcinoma origin to auranofin.
Materials and methods

Chemicals
All chemicals were purchased from Sigma-Aldrich, UK unless indicated otherwise. Anti-53BP1 antibody (Rabbit polyclonal) was purchased from Novus Biologicals, UK. Rabbit polyclonal antibodies against PARP, Nrf2 and Actin were purchased from Cell Signalling Technology, Danvers, MA. Alexa Fluor 488-labelled anti-rabbit antibody was purchased from Molecular Probes, UK.
Cell culture and treatments
Ovarian cancer cell lines were a kind gift from Prof Hani Gabra, Hammersmith Hospital, Imperial College London, UK. Cells were maintained in RPMI-1640 (Gibco, Paisley, UK) and the medium was supplemented with 10 % fetal bovine serum (Gibco) 50 U/ml penicillin (Gibco) and 50 mg/ml streptomycin (Gibco) and maintained at 37 °C in a humidified 5 % 
Western blotting
Following experimental treatments, cells (0.3 x 10 6 ) were removed from the flasks by scraping.
The whole cell lysate preparation and Western blotting were carried out as previously reported (14) .
Statistical analysis
Results are reported as the mean ± SEM. Two tailed independent Student's t test without equal variance assumption was used to determine p-values (*, P < 0.05; **, P < 0.005, ***, P < 0.0005),). Significance of differences in 53BP1 foci numbers between auranofin treated OVCAR5 and IGROV1 cells were assessed using unpaired Student's two-tailed t-test and significance of differences in 53BP1 foci numbers between auranofin treated and respective control cells were assessed using paired Student's two-tailed t-test. Regression analysis was performed to determine the linear relationship between membrane fluidity and % cell survival.
Analysis was performed using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.
Results
Positive correlation between membrane fluidity and auranofin sensitivity: IGROV1 is more fluid and sensitive than OVCAR5
The studies on membrane fluidity and chemo resistance have mainly been restricted to a single breast cancer cell line MCF-7 and its drug resistant variant (2). Our aims were to do a comparative analysis of membrane fluidity in two ovarian cancer cell lines (OVCAR5 & IGROV1) of adenocarcinoma origin (16, 17) and to further investigate how membrane fluidity influences sensitivity of these cell lines to auranofin. Electron spin resonance (ESR) using the spin label 5-DS allowed the determination of membrane order parameter S, which is inversely proportional to membrane fluidity. ESR analysis revealed relatively rigid membranes in OVCAR5 as inferred by an increased S value ( Figure 1A ). In contrast, IGROV1 appeared to have a relatively fluidised membrane as demonstrated by a decreased S value ( Figure 1A ).
Auranofin is known to exhibit cytotoxic activity against various cancer cells (8,9).
Assessment of viability at a wide range of concentrations showed IGROV1 cells were more sensitive to auranofin induced cytotoxicity than OVCAR5 cells (Figure 1 B) . Treatment of auranofin at 1 µM resulted in more than 55 % cell death in IGROV1 compared to less than 10 % in OVCAR5 (Figure 1 C) 
Auranofin induces increased DNA double strand breaks (DSBs) in IGROV1cells
We have previously reported that BRCA1-depleted ovarian cancer cells exhibit increased sensitivity to auranofin due to the accumulation of unrepaired lethal DNA DSBs (10) . In order to understand whether decreased survival exhibited by IGROV1 cells correlate with DNA damage, generation of DSBs were analysed by immunofluorescence using anti-bodies against 53BP1. Upon double strand breaks, 53BP1 along with other DNA repair proteins relocates to the sites of DSBs to form discrete foci. Hence, analysing 53BP1 leads to indirect quantitative assessment of DSBs as reported earlier (18, 19) . Immunostaining of 53BP1 showed discrete foci marking DSBs in auranofin treated cells (Figure 2 A) . As shown in the figure 2 A and B, the number of foci is significantly higher in IGROV1 compared to OVCAR5 upon auranofin treatment. Intriguingly, there was more DSBs in untreated OVCAR5 cells and the number of DSBs does not significantly changed after auranofin treatment ( Figure 2B ). However, the number of cells exhibiting more than 10 foci has increased significantly after 6 h and 18 h following auranofin treatment of IGROV1 cells ( Figure 2B ). Furthermore, auranofin induced DSBs were significantly higher in IGROV1 cells than OVCAR4, another ovarian cancer cell line which possess a comparatively rigid membrane (Supplementary figure 3) . Taken together, the increased number of DSBs in IGROV1 is corroborated by the decreased survival which in turn correlated with the increased membrane fluidity.
Increased cellular oxidation and apoptosis in auranofin-treated IGROV1 cells
We have reported earlier that auranofin induces oxidative stress and apoptosis in BRCA1- 
